Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (NY: BHC )

8.529 -0.101 (-1.17%)
Streaming Delayed Price Updated: 10:04 AM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bausch Health Companies Inc

< Previous 1 2 3 4 5 Next >
Bausch Health to Announce First-Quarter 2024 Results on May 2
Via ACCESSWIRE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Via ACCESSWIRE
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Via ACCESSWIRE
Salix Announces 2024 Gastrointestinal Health Scholars Program
Via ACCESSWIRE
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Via ACCESSWIRE
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Via ACCESSWIRE
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Via ACCESSWIRE
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
Via ACCESSWIRE
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Via ACCESSWIRE
Bausch Health Companies to Present at Cowen Annual Health Care Conference
Via ACCESSWIRE
Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
Via ACCESSWIRE
Bausch Health Unveils "Looking Forward" - A New DTC Television Campaign for Seasonal Affective Disorder (SAD)
Via ACCESSWIRE
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Via ACCESSWIRE
Bausch Health Announces Board Refreshment
Via ACCESSWIRE
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
Via ACCESSWIRE
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
Via ACCESSWIRE
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
Via ACCESSWIRE
DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
Via ACCESSWIRE
3 cheap 'stock'-ing stuffers Wall Street is bullish on
These three companies have Wall Street feeling bullish and are trading under $10, making them ideal ‘stock'-ing stuffers for hard to shop for traders. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
Via ACCESSWIRE
Bausch Health Companies Inc. (NYSE:BHC) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 12/01/2023 -- An investigation on behalf of current long-term investors in shares of Bausch Health Companies Inc. (NYSE:BHC) concerning potential breaches of fiduciary... 
Via SBWire
The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
Via ACCESSWIRE
CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
Via ACCESSWIRE
As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)
Via ACCESSWIRE
Bausch Health Announces Third-Quarter 2023 Results
Via ACCESSWIRE
U.S. District Court Dismisses Norwich's Lawsuit Against the FDA
Via ACCESSWIRE
FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older
Via ACCESSWIRE
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.